Atryn Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical need for antithrombin replacement, success in hereditary antithrombin deficiency management, regulatory approvals for recombinant proteins, hospital adoption for surgical risk, advancement in transgenic biologics.

The growth in the forecast period can be attributed to increasing diagnosis of inherited thrombophilia, rising surgical intervention rates, expansion of biologic anticoagulant use, improved clinician awareness, growth in personalized coagulation therapy. Major trends in the forecast period include growing use of recombinant antithrombin therapies, increased focus on rare coagulation disorders, expansion of preventive thrombosis management, improved surgical risk management in high risk patients, rising adoption of biologic anticoagulants.

The rising prevalence of chronic conditions is expected to drive the growth of the atryn market in the coming years. Chronic conditions are long-term health issues that persist over time and typically require ongoing management or treatment. Factors contributing to the rise in chronic conditions include an aging population, unhealthy lifestyles, and improved healthcare access and management. Atryn, a recombinant antithrombin therapy, helps patients with chronic conditions by preventing harmful blood clots, reducing the risk of severe complications, and supporting better long-term health outcomes. For instance, in April 2022, according to the National Association of Chronic Disease Directors (NACDD), a US-based non-profit organization focused on chronic disease programs, nearly 60% of adult Americans have at least one chronic disease, with approximately 40% experiencing multiple chronic conditions (MCC). This is projected to cost the US economy $2 trillion annually, or $8,600 per person by 2030. Therefore, the rise in chronic conditions is driving the growth of the atryn market.

The increasing focus on personalized medicine is expected to further propel the growth of the atryn market. Personalized medicine tailors medical treatments to an individual’s genetic makeup, environment, and lifestyle to optimize efficacy and minimize adverse effects. The growing emphasis on personalized medicine stems from its ability to improve treatment outcomes, optimize healthcare resources, and address rising patient demand. Atryn contributes to personalized medicine by providing precise, targeted treatment for patients with specific antithrombin deficiencies, enhancing safety and effectiveness in preventing life-threatening clotting disorders during critical medical procedures. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based organization promoting personalized medicine, the U.S. Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022. Therefore, the increasing focus on personalized medicine is driving the growth of the atryn market.

Leading companies in the atryn market are focusing on enhancing advanced biomanufacturing solutions, such as cell-culture-based recombinant protein production, to improve output efficiency, product quality, and meet growing global demand for biologics. Cell-culture-based recombinant protein production involves using genetically engineered mammalian, bacterial, or yeast cells to produce therapeutic proteins. For instance, in October 2023, LFB Biomanufacturing, a France-based biotechnology company, launched a project to expand its bioproduction capacity at the Alès site under the France 2030 plan. This expansion aims to increase the production of innovative cell-culture-derived therapies, strengthen the nation’s biomanufacturing sector, and advance treatments for rare diseases.

Major companies operating in the atryn market are rEVO Biologics Inc.

North America was the largest region in the atryn market in 2025. The regions covered in the atryn market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atryn market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately impacted the atryn market by increasing costs related to recombinant protein production and specialized biologic manufacturing infrastructure. These impacts are most visible in hospital and specialty clinic procurement. Higher tariffs have contributed to pricing pressure for rare coagulation disorder treatments. At the same time, tariffs are supporting domestic biologics innovation and production. This enhances long term access to recombinant antithrombin therapies.

The atryn market research report is one of a series of new reports that provides atryn market statistics, including atryn industry global market size, regional shares, competitors with a atryn market share, detailed atryn market segments, market trends and opportunities, and any further data you may need to thrive in the atryn industry. This atryn market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Atryn is a recombinant human antithrombin protein produced using genetically engineered goats. It is used to prevent blood clots in patients with hereditary antithrombin deficiency, especially during high-risk situations such as surgery or childbirth.

The primary routes of administration for Atryn are intravenous (IV) and subcutaneous (SC). IV administration delivers the medication directly into a vein, allowing for rapid absorption and precise dosing, making it ideal for emergencies or situations requiring immediate therapeutic effect. The product is distributed through multiple channels, including direct sales, retail pharmacies, and online pharmacies. Its applications include hereditary antithrombin deficiency, acquired antithrombin deficiency, and other related conditions, and it is used by hospitals, specialized clinics, and home care settings.

The atryn market includes revenues earned by entities by recombinant human antithrombin, biologic drug formulations, and active pharmaceutical ingredients (APIs). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.